Biomarkers in Metastatic Colorectal Cancer

Marina Kacevska, Graham R Robertson, Stephen J Clarke, Christopher Liddle, Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing Expert Opinion on Drug Metabolism & Toxicology. ,vol. 4, pp. 137- 149 ,(2008) , 10.1517/17425255.4.2.137

Eric Van Cutsem, Emilio Bajetta, Juan Valle, Claus-Henning Köhne, J. Randolph Hecht, Malcolm Moore, Colin Germond, William Berg, Bee-Lian Chen, Tarja Jalava, David Lebwohl, Gerold Meinhardt, Dirk Laurent, Edward Lin, Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma Journal of Clinical Oncology. ,vol. 29, pp. 2004- 2010 ,(2011) , 10.1200/JCO.2010.29.5436

Carolyn D. Runowicz, Gary L. Rosner, Michelle Shayne, Alex Sparreboom, Lara E. Sucheston, Gary H. Lyman, Jennifer J. Griggs, Pamela B. Mangu, Holly Anderson, Edward P. Balaban, James J. Dignam, William M. Hryniuk, Vicki A. Morrison, T. May Pini, Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Journal of Clinical Oncology. ,vol. 30, pp. 1553- 1561 ,(2012) , 10.1200/JCO.2011.39.9436

Kaoru Shimokata, Yuichi Ando, Yoshinori Hasegawa, Hideo Saka, Hiroshi Ueoka, Maki Ando, Kei Muro, Akira Yokoyama, Soh Saitoh, Toshiyuki Sawa, Polymorphisms of UDP-Glucuronosyltransferase Gene and Irinotecan Toxicity: A Pharmacogenetic Analysis Cancer Research. ,vol. 60, pp. 6921- 6926 ,(2000)

J. Randolph Hecht, Tanja Trarbach, John D. Hainsworth, Pierre Major, Elke Jäger, Robert A. Wolff, Katherine Lloyd-Salvant, György Bodoky, Kelly Pendergrass, William Berg, Bee-Lian Chen, Tarja Jalava, Gerold Meinhardt, Dirk Laurent, David Lebwohl, David Kerr, Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma Journal of Clinical Oncology. ,vol. 29, pp. 1997- 2003 ,(2011) , 10.1200/JCO.2010.29.4496

Michael S. Braun, Susan D. Richman, Philip Quirke, Catherine Daly, Julian W. Adlard, Faye Elliott, Jennifer H. Barrett, Peter Selby, Angela M. Meade, Richard J. Stephens, Mahesh K.B. Parmar, Matthew T. Seymour, Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial Journal of Clinical Oncology. ,vol. 26, pp. 2690- 2698 ,(2008) , 10.1200/JCO.2007.15.5580

M Gusella, A C Frigo, C Bolzonella, R Marinelli, C Barile, A Bononi, G Crepaldi, D Menon, L Stievano, S Toso, F Pasini, E Ferrazzi, R Padrini, Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer British Journal of Cancer. ,vol. 100, pp. 1549- 1557 ,(2009) , 10.1038/SJ.BJC.6605052

Christos S. Karapetis, Shirin Khambata-Ford, Derek J. Jonker, Chris J. O'Callaghan, Dongsheng Tu, Niall C. Tebbutt, R. John Simes, Haji Chalchal, Jeremy D. Shapiro, Sonia Robitaille, Timothy J. Price, Lois Shepherd, Heather-Jane Au, Christiane Langer, Malcolm J. Moore, John R. Zalcberg, K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England Journal of Medicine. ,vol. 359, pp. 1757- 1765 ,(2008) , 10.1056/NEJMOA0804385

Yoshinori Shirota, Jan Stoehlmacher, Jan Brabender, Yi-Ping Xiong, Hiroyuki Uetake, Kathleen D. Danenberg, Susan Groshen, Denise D. Tsao-Wei, Peter V. Danenberg, Heinz-Josef Lenz, ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy Journal of Clinical Oncology. ,vol. 19, pp. 4298- 4304 ,(2001) , 10.1200/JCO.2001.19.23.4298

Adrian M. Jubb, Herbert I. Hurwitz, Wei Bai, Eric B. Holmgren, Patti Tobin, A. Steven Guerrero, Fairooz Kabbinavar, Scott N. Holden, William F. Novotny, Gretchen D. Frantz, Kenneth J. Hillan, Hartmut Koeppen, Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 24, pp. 217- 227 ,(2006) , 10.1200/JCO.2005.01.5388